Pharmacologic characteristics of progestins used for contraception and hormone replacement therapy, including new transdermal technologies.
Structural differences among progestins account for their unique properties. Pharmacologic principles should be used when considering the appropriate progestational agent to achieve both clinical and economic outcomes. Use of the same progestin in oral contraceptives (OCs) and hormone replacement therapy (HRT) allows for a seamless transition from OCs to HRT, while maintaining the health benefits of the OC. A pharmacologically based approach also has been used in developing the first transdermal contraceptive system, which is expected to be on the market in early 2002.